Regulatory News has published 1 story about Betta Pharmaceuticals on 25 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 25 September 2026.
This page is generated from Regulatory News’ editorial coverage of Betta Pharmaceuticals. It is not an advertisement.
On the record
- Company
- Betta Pharmaceuticals Co., Ltd. (Shenzhen: 300558)
- Headquarters
- Hangzhou, China (Xcovery Holdings, the ensartinib filer, is based in Palm Beach Gardens, Florida)
- Founded
- 2003, by Ding Lieming, who remains Chairman and Chief Executive Officer
- Regulator
- European Medicines Agency (CHMP); European Commission decision pending
- Latest milestone
- CHMP positive opinion, Gevalka (ensartinib)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
